ENTITY

Takeda Pharmaceutical (4502 JP)

214

Analysis

Health Care • Japan

Takeda Pharmaceutical Co Ltd focuses on the Research & Development, Manufacturing, Sales and Marketing and Import/Export of Pharmaceutical Drugs. The Company focuses on the following core therapeutic areas: Cardiovascular & Metabolic, Oncology, Central Nervous System, Respiratory & Immunology, General Medicine (Gastrointestinal & Genitourinary) and Vaccine.

more

Refresh

Exchange Announcement • 19 Apr 2024 07:00

U.S. Fda Approves Subcutaneous Administration Of Takeda’S Entyvio For Maintenance Therapy In Moderately To Severely Active Crohn’S Disease

Exchange Announcement • 15 Apr 2024 12:00

Notice Regarding Issuance Of Jpy Hybrid Bonds

Exchange Announcement • 27 Mar 2024 07:00

Takeda Announces Candidates For Board Of Directors At Upcoming Shareholders Meeting

Exchange Announcement • 09 Feb 2024 07:00

Takeda Intends To Rapidly Initiate The First Global Phase 3 Trials Of An Oral Orexin Agonist In Narcolepsy Type 1 In First Half Of Fiscal Year 2024

Exchange Announcement • 02 Feb 2024 15:00

Quarterly Securities Report (The Third Quarter Of 147th Business Term) For The Nine-Month Period And Three-Month Quarter Ended December 31, 2023

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.30.3

x